About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
BMRN - BioMarin Pharmaceuti...| Previous Close | $77.50 | Open | $77.56 |
| Volume | 1.49M | Market Cap | 14.055B |
| Yield | Last Dividend |
| BioMarin Pharmaceutical Inc. (NASDAQ:BMR... | 1:58 PM |
| Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) have received a consensus recommendation of ???Hold??? from the twenty-nine ratings firms that ar... | |
| BioMarin to Host Third Quarter 2020 Fina... | 7:30 AM |
| SAN RAFAEL, Calif., Oct. 22, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaim??, Chairman an... | |
| Zacks: Brokerages Anticipate BioMarin Ph... | 10/21/20 |
| Analysts predict that BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) will report $460.13 million in sales for the current fiscal quarter, according to Zac... | |
| BioMarin Pharmaceutical Inc. (NASDAQ:BMR... | 10/20/20 |
| Wall Street brokerages predict that BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) will post earnings per share (EPS) of $0.25 for the current fiscal quar... | |
| Brokerages Set BioMarin Pharmaceutical I... | 10/20/20 |
| Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) have been given an average recommendation of ???Hold??? by the twenty-nine brokerages that are pr... | |
| The Klein Law Firm Reminds Investors of ... | 10/19/20 |
| NEW YORK, NY / ACCESSWIRE / October 19, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of ... | |
| ROSEN, A TOP RANKED LAW FIRM, Reminds Bi... | 10/15/20 |
| NEW YORK , Oct. 15, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioMarin Pharmaceu... | |
| Medical Foods for Inborn Errors of Metab... | 10/12/20 |
| The medical foods for inborn errors of metabolism market are anticipated to reach US$ 5,768.79 million by 2027 from US$ 2,507.80 million in 2019. The ... | |
| Phenylketonuria Treatment Market 2020| E... | 10/09/20 |
| Phenylketonuria Treatment market growth prospects have been changing all over the globe and this report provides you with an in-detail account of the ... | |
| Global Hemophilia A Drug Market 2020 to ... | 10/08/20 |
| The new statistical report has recently published by Reports Consultant to its massive repository titled Global Hemophilia A Drug market 2020. This in... | |
| BioMarin, Pioneer in Rare Disease Treatm... | 10/07/20 |
| SAN RAFAEL, Calif., Oct. 7, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the U.S. Food and Drug Administration... | |
| Scientific Luminary and MacArthur Fellow... | 10/05/20 |
| SAN RAFAEL, Calif., Oct. 5, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced the Company hired scientific luminary and ... | |
| ROSEN, A LEADING INVESTOR RIGHTS LAW FIR... | 10/02/20 |
| NEW YORK, Oct. 2, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of ... | |
| The Law Offices of Frank R. Cruz Announc... | 10/02/20 |
| LOS ANGELES--(BUSINESS WIRE)---- $BMRN #classaction--The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf o... | |
| BioMarin's gene therapy nabs accelerated... | 10/02/20 |
| The FDA has designated Fast Track status to BioMarin Pharmaceutical's (NASDAQ:BMRN) BMN-307, an investigational gene therapy for the treatment of phen... | |
| BIOMARIN SHAREHOLDER ALERT by Former Lou... | 09/30/20 |
| NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (???KSF???) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind i... | |
| BMRN Shareholder Alert: Bronstein, Gewir... | 09/30/20 |
| NEW YORK, Sept. 30, 2020 /PRNewswire/ -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has ... | |
| HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS,... | 09/28/20 |
| SAN FRANCISCO, Sept. 28, 2020 /PRNewswire/ -- Hagens Berman urges BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) investors to contact the firm now. A sec... | |
| BMRN INVESTIGATION ALERT: Bernstein Lieb... | 09/28/20 |
| NEW YORK--(BUSINESS WIRE)--Bernstein Liebhard, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on ... | |
| BMRN LOSSES ALERT: Bernstein Liebhard is... | 09/27/20 |
| NEW YORK--(BUSINESS WIRE)--Bernstein Liebhard, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on ... | |
| BioMarin to Participate in Four Upcoming... | 09/15/20 |
| SAN RAFAEL, Calif., Sept. 15, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in fou... | |
| Attention Biotech Investors: Mark Your C... | 09/01/20 |
| August was a disappointing month as far as regulatory decisions are concerned. The FDA turned down several applications, citing different reasons. Not... | |
| BioMarin Pharmaceuticals: Appealing Afte... | 08/24/20 |
| BioMarin has seen a big setback in approval of its hemophilia A candidate, although it might just be a delay. | |
| BioMarin's FDA Setback Opens New Opportu... | 08/21/20 |
| A simple covered call strategy seems appropriate here???.CVX | |
| Biomarin, Gilead drug rejections don't s... | 08/21/20 |
| It???s tempting to interpret the FDA's surprise rejections of two drugs this week as an agency-wide downshift. But that would be a mistake. | |
| BioMarin Stock???s Near-Term Growth Is G... | 08/20/20 |
| After the U.S. Food and Drug Administration rebuffed the biotech???s request to approve its gene therapy for hemophilia, BioMarin???s rivals may catch... | |
| BioMarin Submits New Drug Application to... | 08/20/20 |
| SAN RAFAEL, Calif., Aug. 20, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that it has submitted a New Drug Applica... | |
| BioMarin: Not Approved Until It's Approv... | 08/19/20 |
| The FDA wants to see two more years of data to see how far the Factor VIII levels drop, a primary endpoint of annualized bleeding rate, and safety mon... | |
| Stocks on the Move: Gilead Sciences on F... | 08/19/20 |
| Yahoo Finance's On the Move panel discuss today's Stocks on the Move: Gilead Sciences and Biomarin Pharmaceutical | |
| 5 Top Stock Trades for Thursday: TGT, LO... | 08/19/20 |
| Nvidia, BioMarin, Visa, Lowe's and Target were our top stock trades. That said, let's look at what the charts are telling us now. | |
| Buy rating | 09/10/20 |
| Truist Securities maintains Buy rating and lowers Price Target from $130.00 to $125.00 | |
| Hold rating | 08/21/20 |
| Morgan Stanley maintains Equal-Weight rating and lowers Price Target from $125.00 to $85.00 | |
| Hold rating | 08/20/20 |
| Citigroup downgrades from Buy to Neutral rating and lowers Price Target from $148.00 to $86.00 | |
| Hold rating | 08/20/20 |
| RBC Capital downgrades from Outperform to Sector Perform rating and lowers Price Target from $123.00 to $92.00 | |
| Buy rating | 08/20/20 |
| Canaccord Genuity maintains Buy rating and lowers Price Target from $119.00 to $95.00 | |
| Hold rating | 08/19/20 |
| Stifel downgrades from Buy to Hold rating and lowers Price Target from $127.00 to $100.00 | |
| Strong Buy rating | 08/19/20 |
| SVB Leerink maintains Outperform rating and lowers Price Target from $140.00 to $113.00 | |
| Buy rating | 08/06/20 |
| BMO Capital maintains Market Perform rating and raises Price Target from $94.00 to $108.00 | |
| Strong Buy rating | 08/05/20 |
| SVB Leerink maintains Outperform rating and raises Price Target from $130.00 to $140.00 | |
| Date | 2020-08-04 (AMC) | Est. (EPS/Rev.) | ($0.11)/ 418.61M |
| Actual (EPS/Rev.) | $-0.16/ $429.49 M | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Alpha Swing Trades | Jonathan | 68.00 % | Follow |
| Lewis Aung's long pick | Kyaw Aung | 66.00 % | Subscribe |
| Best Trading Ideas | Best Trading Ideas | 53.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
